APA (7th ed.) Citation

Boku, N., Omori, T., Shitara, K., Sakuramoto, S., Yamaguchi, K., Kato, K., . . . Kang, Y. (2024). Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer. Gastric Cancer, 27(6), 1287-1301. https://doi.org/10.1007/s10120-024-01535-0

Chicago Style (17th ed.) Citation

Boku, Narikazu, et al. "Nivolumab Plus Chemotherapy in Patients with HER2-negative, Previously Untreated, Unresectable, Advanced, or Recurrent Gastric/gastroesophageal Junction Cancer." Gastric Cancer 27, no. 6 (2024): 1287-1301. https://doi.org/10.1007/s10120-024-01535-0.

MLA (9th ed.) Citation

Boku, Narikazu, et al. "Nivolumab Plus Chemotherapy in Patients with HER2-negative, Previously Untreated, Unresectable, Advanced, or Recurrent Gastric/gastroesophageal Junction Cancer." Gastric Cancer, vol. 27, no. 6, 2024, pp. 1287-1301, https://doi.org/10.1007/s10120-024-01535-0.